|30th September 2020||Mark A Goldsmith||42,548||Exercise of derivative||$4.73||$201,252.04|
|30th September 2020||Mark A Goldsmith||1,312||Open or private sale||$34.12||$44,762.29|
|30th September 2020||Mark A Goldsmith||42,578||Open or private sale||$34.40||$1,464,853.51|
|30th September 2020||Mark A Goldsmith||30||Exercise of derivative||$1.12||$33.60|
|29th September 2020||Mark A Goldsmith||21,088||Open or private sale||$34.08||$718,651.63|
|29th September 2020||Mark A Goldsmith||20,076||Exercise of derivative||$4.73||$94,959.48|
|29th September 2020||Mark A Goldsmith||30,523||Open or private sale||$34.14||$1,041,917.87|
|29th September 2020||Mark A Goldsmith||10,447||Exercise of derivative||$4.09||$42,728.23|
|28th September 2020||Mark A Goldsmith||10,132||Exercise of derivative||$4.09||$41,439.88|
|28th September 2020||Mark A Goldsmith||10,132||Open or private sale||$34.11||$345,567.06|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of novel therapeutics in the field of epigenetics. Its product candidates include CPI-0610, CPI-1205, and CPI-0209.